Matthew C. Abernethy

Matthew C. Abernethy

DirectoratNeurocrine Biosciences· In proxies 2020–2025

Pay in FY2023+23% from the year before · Neurocrine Biosciences stock +10.3% the same year

Matthew C. Abernethy was paid $6.1M in FY2023 (Dec), up 23%. Neurocrine Biosciences stock rose 10.3% that year.

Pay$100 in the stock at the end of FY19 → $123
Pay is from the Summary Compensation Table of each Neurocrine Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fate TherapeuticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Neurocrine BiosciencesPublic company · 6 yr
    • Chief Financial Officer2020 – Present · 6 yrStock in role +33%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?